<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525639</url>
  </required_header>
  <id_info>
    <org_study_id>MIAMI GR-2013-02356832</org_study_id>
    <nct_id>NCT03525639</nct_id>
  </id_info>
  <brief_title>CMR Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance</brief_title>
  <acronym>MIAMI</acronym>
  <official_title>Cardiac Magnetic Resonance Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonio Esposito</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute myocarditis (AM) usually experience spontaneous healing, but a
      considerable percentage of them evolve toward chronic cardiac impairment at long-term. The
      evolution toward dilated cardiomypathy (DCM) occurs in a subtle manner, frequently after an
      initial recover that mimics complete healing. Differences in the course of disease may
      reflect the course of underlying myocardial inflammation related to viral clearance or
      persistence and to the following autoimmunity response.

      New cardiac magnetic resonance (CMR) parameters are sensitive to myocardial inflammation.
      They may have a prognostic role and, in particular, our hypothesis is that a short-term
      monitoring with CMR (1 month) may identify the subgroup of patients at high risk to progress
      toward DCM. The trend of CMR parameters during the first month will be compared with the
      following outcome in 80 patients with AM.

      Results of this study will help to significantly improve management and outcome of patients
      with AM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Significance

      In patients with acute myocarditis (AM), spontaneous improvement can be observed in most of
      cases, but progression toward a dilated cardiomyopathy is a not rare outcome (around 20% of
      patients) (Feldmann NEJM 2000;343:1388-98). Differences in the course of disease may reflect
      course of underlying viral infection. In a large series of patients with AM submitted to two
      endo-myocardial biopsies (EMBs) in few months, Kuhl demonstrated that viral clearance was
      associated with spontaneous ejection fraction (EF) improvement, while EF did not improve or
      even deteriorated in patients with viral and myocardial inflammation persistence (Kühl
      Circulation 2005;111:887-93. Kühl Circulation 2005;112:1965-70). However, repeated EMBs
      cannot be proposed in the clinical routine and, hence, non-invasive detection of the subgroup
      of patients with inflammation persistence should have important implications. Today, Cardiac
      Magnetic Resonance (CMR) is recognized as an accurate non-invasive imaging tool to diagnose
      acute myocarditis, because of its ability to detect myocardial inflammation and necrosis
      (Friedrich JACC 2009;53:1475-87). However, although the role of CMR parameters of
      inflammation and necrosis is fairly well established in diagnosis of AM, any study
      investigated the potential value of these parameters in the assessment of inflammation
      persistence after acute phase. We aspect the assessment of early changes in CMR parameters at
      a second imaging study may have great value in outcome prediction.

      Hypothesis: The persistence of a subtle myocardial inflammation is an important factor in
      determining a negative outcome in patients with acute myocarditis; moreover, CMR demonstrated
      to assess myocardial inflammation with high sensitivity and, hence, has the potentiality to
      follow the myocardial inflammation over time.

      Our hypothesis is that a short term monitoring with CMR (1 month) may allow differentiating
      patients evolving toward a complete healing from patients with persistent myocardial
      inflammation, which may have a greater risk to progress toward DCM.

      Preliminary data: A previous study from our group, performed on patients with chronic
      inflammatory cardiomyopathy, demonstrated as the positivity of CMR parameters of necrosis
      (LGE) and inflammation (Edema) is significantly higher in patients with an active
      inflammation at EMB, compared to patients with borderline histological criteria (De Cobelli
      2006 JACC;47:1649-54). These data suggest the possibility to detect subtle myocardial
      inflammation persistence with CMR in patients with chronicization of an acute myocarditis.

      Moreover, Wagner and Colleagues demonstrated, in a small group of patients, a correlation
      between CMR evidence of myocardial hyperemia persistence 4 weeks after the onset of acute
      myocarditis and the negative LV-remodeling 30 months later (Wagner A 2003 MAGMA;16:17-20).

      Currently, the three Unit involved in this project are collecting a common register of all
      patients submitted to a CMR study for the assessment of an acute myocarditis; this work
      collecting imaging features of several patients (&gt; 100) allows to compare and standardize the
      protocols of acquisition and post-processing of CMR studies.

      Materials and Methods This is a prospective multicenter cohort study. 80 patients with
      diagnosis of acute myocarditis (AM) will be enrolled.

      All patients admitted to Hospital with suspect of AM will be submitted to:

      collection of detailed anamnesis and physical examination, 12-lead ECG, laboratory exams,
      transthoracic echocardiography, coronary catheterization or coronary CT angiography when an
      ischemic cause of symptoms need to be excluded and CMR imaging within 3-5 days.

      All patients with clinically or EMB confirmed diagnosis of AM will be enrolled and will
      undergo a second CMR study 1 month later. Percentage of change in global Relative Enhancement
      (gRE), T2-ratio and amount of LGE between the two CMR studies will be assessed.

      All patients will undergo to a clinical/instrumental follow-up including: CMR assessment of
      LV ejection fraction and enddiastolic after at least 1 year from diagnosis; registration of
      all-cause mortality, cardiac death and aborted cardiac sudden death in patients with ICD.

      Impact and Translational Implications Myocarditis is characterized by significant
      heterogeneity of long-term evolution. CMR could play a key role in the noninvasive and early
      identification of patients with persistent myocardial inflammation, at high risk to evolve
      toward an irreversible post-myocarditis heart failure. So CMR may help to design tailored
      management of patients. In this perspective, invasive characterization of damage mechanism
      and aetiology might be reserved to patients with CMR evidence of inflammation persistence
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early changes in CMR parameters reflecting inflammation activity (% of gRE [global Relative Enhancement], T2-ratio and LGE amount)</measure>
    <time_frame>1 month</time_frame>
    <description>To assess the prognostic value of the early changes in CMR parameters reflecting inflammation activity in terms of myocardial oedema, hyperemia and tissue necrosis, in order to identify the subgroup of patients with greater risk to develop dilated cardiomyopathy (DCM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative CMR parameters of structural tissue alteration (native T1 mapping, ECV quantification [extracellular volume], T2 mapping).</measure>
    <time_frame>Inclusion; 1 month</time_frame>
    <description>To assess the prognostic value of new quantitative CMR parameters of structural tissue alteration, such as T1 relaxation time (T1 mapping), extracellular volume (ECV) and T2 relaxation time (T2 mapping).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myocarditis Acute</condition>
  <condition>Myocardial Inflammation</condition>
  <arm_group>
    <arm_group_label>Patients with Acute Myocarditis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing Cardiac Magnetic Resonance at inclusion, 1 month, 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance</intervention_name>
    <description>Additional CMR study 1 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (1-month-CMR).</description>
    <arm_group_label>Patients with Acute Myocarditis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of at least 1 of the subsequent clinical features [12]:

               -  Acute chest pain (pericarditic, or pseudo-ischaemic)

               -  New-onset dyspnoea at rest or during exercise

               -  Fatigue with or without left/right heart failure signs

               -  Palpitation or unexplained arrhythmia symptoms or syncope or aborted sudden
                  cardiac death

               -  Unexplained cardiogenic shock

          -  Associated with at least 1 of the subsequent diagnostic criteria [12]:

               -  Newly abnormal 12 lead ECG and/or Holter and/or stress testing, any of the
                  following: I to III degree AV block, or bundle branch block, ST/T wave change,
                  sinus arrest, ventricular tachycardia or fibrillation and asystole, atrial
                  fibrillation, reduced R wave height, intraventricular conduction delay, abnormal
                  Q waves, low voltage, frequent premature beats, supraventricular tachycardia

               -  Myocardiocytolysis markers (elevated TnT/TnI)

               -  New, otherwise unexplained LV and/or RV functional and/or structural
                  abnormalities on cardiac imaging (echo/angio/CMR) compatible with AM and
                  excluding other diseases

          -  Signed informed consent

        Exclusion Criteria:

          -  History of cardiomyopathies

          -  Coronary artery disease (coronary catheterization or CT angiography will be performed
             when CAD need to be excluded in consideration of signs and symptoms)

          -  ICD or pacemaker

          -  Inability to hold breath or to lay down for 45 min

          -  Claustrophobia

          -  Recent history of alimentary/alcoholic/respiratory intoxication

          -  CMR diagnostic criteria suggestive of other cardiac disease explaining signs and
             symptoms (e.g. myocardial infarction with patent coronary arteries, tako-tsubo
             syndrome)

          -  Risk for nephrogenic systemic fibrosis (eGFR &lt; 30mL/min/1.73m2)

          -  History of allergic reaction to MR contrast media

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Esposito</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Esposito</last_name>
    <email>esposito.antonio@unisr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Palmisano</last_name>
    <email>palmisano.anna@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Esposito</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Galea</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Faletti</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Youn JC, Shim HS, Lee JS, Ji AY, Oh J, Hong N, Lee HS, Park S, Lee SH, Choi D, Chung N, Kang SM. Detailed pathologic evaluation on endomyocardial biopsy provides long-term prognostic information in patients with acute myocarditis. Cardiovasc Pathol. 2014 May-Jun;23(3):139-44. doi: 10.1016/j.carpath.2014.01.004. Epub 2014 Jan 17.</citation>
    <PMID>24529879</PMID>
  </reference>
  <reference>
    <citation>Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, Salvi A, Perkan A, Di Lenarda A, Bussani R, Bartunek J, Sinagra G. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation. 2013 Nov 26;128(22):2384-94. doi: 10.1161/CIRCULATIONAHA.113.003092. Epub 2013 Oct 1.</citation>
    <PMID>24084750</PMID>
  </reference>
  <reference>
    <citation>Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012 Feb 25;379(9817):738-47. doi: 10.1016/S0140-6736(11)60648-X. Epub 2011 Dec 18. Review.</citation>
    <PMID>22185868</PMID>
  </reference>
  <reference>
    <citation>Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with &quot;idiopathic&quot; left ventricular dysfunction. Circulation. 2005 Feb 22;111(7):887-93. Epub 2005 Feb 7.</citation>
    <PMID>15699250</PMID>
  </reference>
  <reference>
    <citation>Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005 Sep 27;112(13):1965-70. Epub 2005 Sep 19.</citation>
    <PMID>16172268</PMID>
  </reference>
  <reference>
    <citation>Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009 Apr 28;53(17):1475-87. doi: 10.1016/j.jacc.2009.02.007.</citation>
    <PMID>19389557</PMID>
  </reference>
  <reference>
    <citation>Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006 Oct 10;114(15):1581-90. Epub 2006 Oct 2.</citation>
    <PMID>17015795</PMID>
  </reference>
  <reference>
    <citation>Natale L, De Vita A, Baldari C, Meduri A, Pieroni M, Lombardo A, Crea F, Bonomo L. Correlation between clinical presentation and delayed-enhancement MRI pattern in myocarditis. Radiol Med. 2012 Dec;117(8):1309-19. doi: 10.1007/s11547-012-0790-x. Epub 2012 Feb 10. English, Italian.</citation>
    <PMID>22327917</PMID>
  </reference>
  <reference>
    <citation>Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012 May 1;59(18):1604-15. doi: 10.1016/j.jacc.2012.01.007. Epub 2012 Feb 22.</citation>
    <PMID>22365425</PMID>
  </reference>
  <reference>
    <citation>Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d. doi: 10.1093/eurheartj/eht210. Epub 2013 Jul 3.</citation>
    <PMID>23824828</PMID>
  </reference>
  <reference>
    <citation>De Cobelli F, Pieroni M, Esposito A, Chimenti C, Belloni E, Mellone R, Canu T, Perseghin G, Gaudio C, Maseri A, Frustaci A, Del Maschio A. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol. 2006 Apr 18;47(8):1649-54. Epub 2006 Mar 29.</citation>
    <PMID>16631005</PMID>
  </reference>
  <reference>
    <citation>Wagner A, Schulz-Menger J, Dietz R, Friedrich MG. Long-term follow-up of patients paragraph sign with acute myocarditis by magnetic paragraph sign resonance imaging. MAGMA. 2003 Feb;16(1):17-20.</citation>
    <PMID>12695882</PMID>
  </reference>
  <reference>
    <citation>Francone M, Chimenti C, Galea N, Scopelliti F, Verardo R, Galea R, Carbone I, Catalano C, Fedele F, Frustaci A. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovasc Imaging. 2014 Mar;7(3):254-63. doi: 10.1016/j.jcmg.2013.10.011. Epub 2014 Feb 19.</citation>
    <PMID>24560214</PMID>
  </reference>
  <reference>
    <citation>Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009 Aug;30(16):1995-2002. doi: 10.1093/eurheartj/ehp249. Epub 2009 Jun 25.</citation>
    <PMID>19556262</PMID>
  </reference>
  <reference>
    <citation>Chimenti C, Kajstura J, Torella D, Urbanek K, Heleniak H, Colussi C, Di Meglio F, Nadal-Ginard B, Frustaci A, Leri A, Maseri A, Anversa P. Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure. Circ Res. 2003 Oct 3;93(7):604-13. Epub 2003 Sep 4.</citation>
    <PMID>12958145</PMID>
  </reference>
  <reference>
    <citation>Yeon SB, Salton CJ, Gona P, Chuang ML, Blease SJ, Han Y, Tsao CW, Danias PG, Levy D, O'Donnell CJ, Manning WJ. Impact of age, sex, and indexation method on MR left ventricular reference values in the Framingham Heart Study offspring cohort. J Magn Reson Imaging. 2015 Apr;41(4):1038-45. doi: 10.1002/jmri.24649. Epub 2014 May 12.</citation>
    <PMID>24817313</PMID>
  </reference>
  <reference>
    <citation>Luetkens JA, Doerner J, Thomas DK, Dabir D, Gieseke J, Sprinkart AM, Fimmers R, Stehning C, Homsi R, Schwab JO, Schild H, Naehle CP. Acute myocarditis: multiparametric cardiac MR imaging. Radiology. 2014 Nov;273(2):383-92. doi: 10.1148/radiol.14132540. Epub 2014 Jun 6.</citation>
    <PMID>24910904</PMID>
  </reference>
  <reference>
    <citation>Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res. 2003 Oct 15;60(1):5-10. Review.</citation>
    <PMID>14522402</PMID>
  </reference>
  <reference>
    <citation>Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003 Jun 10;107(22):2793-8. Epub 2003 May 27.</citation>
    <PMID>12771005</PMID>
  </reference>
  <reference>
    <citation>Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003 Feb 18;107(6):857-63.</citation>
    <PMID>12591756</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Antonio Esposito</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cardiac Magnetic Resonance</keyword>
  <keyword>Acute Myocarditis</keyword>
  <keyword>Myocardial Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

